Transformation-defective polyoma middle T antigen mutants defective in PLCγ, PI-3, or src kinase activation enhance ERK2 activation and promote retinoic acid-induced, cell differentiation like wild-type middle T

Experimental Cell Research

Volumn 248, Issue 2, 1999, Pages 538-551

  Yen, Andrew ^a   Cherington, Van ^b   Schaffhausen, Brian ^c   Marks, Kevin ^a   Varvayanis, Susi ^a  

^a Department of Obstetrics Gynecology   (United States)

^b ALG Company   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE; RETINOIC ACID; VIRUS MIDDLE T ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENE; VIRUS CELL TRANSFORMATION;

MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; POLYOMAVIRUS;

EID: 0033134120     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4423     Document Type: Article

References (59)

1. Collins S. J., Gallo R. C., Gallagher R. E. Continuous growth and differentiation lineage specificity: Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 270:1977;347-349.
2. Yen A. HL-60 cells as a model of growth control and differentiation: The significance of variant cells. Hemat. Rev. 4:1990;5-46.
3. Yen A., Forbes M. E., Varvayanis S., Tykocinski M. L., Groger R. K., Platko J. D. C-FMS dependent HL-60 cell differentiation and regulation of RB gene expression. J. Cell Physiol. 157:1993;379-391.
4. Yen A., Sturgill R., Varvayanis S., Chern R. FMS (CSF-1 receptor) prolongs cell cycle, promotes retinoic acid induced hypophosphorylation of RB protein, G1 arrest and cell differentiation. Exp. Cell Res. 229:1996;111-125.
5. Platko J. D., Forbes M. E., Varvayanis S., Williams M. N., Brooks S. C. III, Cherington V., Yen A. Polyoma middle T antigen in HL-60 cells accelerates hematopoietic myeloid and monocytic cell differentiation. Exp. Cell Res. 238:1998;42-50.
6. Weinberg R. Oncogenes and the molecular origins of cancer. Oncogenes of DNA Tumor Viruses. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 223-238.
7. Cooper G. M. Oncogenes. 1995;Jones & Bartlett, Boston.
8. c-src. EMBO J. 3:1984;585-591.
9. c-src. Cell. 50:1987;1031-1037.
10. Cohen B., Liu Y., Druker B., Roberts T. M., Schaffhausen B. S. Characterization of pp85, a target of oncogenes and growth factor receptors. Mol. Cell. Biol. 10:1990;2909-2915.
11. Su W., Liu W., Schaffhausen B. S., Roberts T. M. Association ofPolyomavirus. J. Biol. Chem. 270:1995;12331-12334.
12. De Jeso B., Feliciello A., Pacifico F., Iannelli A., D'Armiento F., Liguoro D., Avvedimento E. V. Inhibition of c-Ras reactivates thyroglobulin synthesis in middle T transformed thyroid cells. Cell Growth Differen. 6:1995;1315-1319.
13. Gudas L. J. Retinoids and vertebrate development. J. Biol. Chem. 269:1994;15399-15402.
14. Mangelsdorf, D. J. Kasukiko, U. Evans, R. M. 1994, The retinoid receptors, In, The Retinoids, M. B. SpornA. RobertsD. S. Goodman, 319, 349, Raven Press, New York.
15. Fanjul A., Dawson M. L., Hobbs P. D., Jong L., Cameron J. F., Harlev E., Graupner G., Lu X. P., Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 372:1994;107-111.
16. Pazin M. J., Kadonaga J. T. What's up and down with histone deactylation and transcription? Cell. 89:1997;325-328.
17. Ogryzko V. V., Schiltz R. L., Russanova V., Howard B. H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell. 87:1996;953-959.
18. Takahashi N., Sausville E. A., Bretiman T. R. N-(4-hydroxyphenyl) retinamide (fenretinide) in combination with retinoic acid enhances differentiation and retinoylation of proteins. Clin. Cancer Res. 1:1995;637-642.
19. Cohen P. S., Letterio J. J., Gaetano C., Chan J., Matsumoto K., Sporn M. B., Thiele C. J. Induction of transforming growth factor beta-1 and its receptor during all-trans-retinoic (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res. 55:1995;2380-2386.
20. Han G. R., Dohi D. F., Lee H. Y., Rajah R., Walsh G. L., Hong W. K., Cohen P., Kurie J. M. All-trans-retinoic acid transforming growth factor-beta-2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J. Biol. Chem. 272:1997;13711-13716.
21. Mihara K., Cao X-R., Yen A., Chandler S., Driscoll B., Murphree A. L., T'Ang A., Fung Y. K. T. Cell-cycle dependent regulation of phosphorylation of the human retinoblastoma gene product. Science. 246:1989;1300-1303.
22. Yen A., Varvayanis S. Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp. Cell Res. 214:1994;250-257.
23. Brooks S. C. III, Kazmer S., Levin A. A., Yen A. Myeloid differentiation and RB phosphorylation changes in HL-60 cells induced by RAR- and RXR-selective retinoic acid analogs. Blood. 87:1996;227-237.
24. Talmage D. A., Listerud M. Retinoic acid suppresses polyoma virus transformation by inhibiting transcription of the c-fos proto-oncogene. Oncogene. 9:1994;3557-3563.
25. Talmage D. A., Lackey R. S. Retinoic acid receptor alpha suppresses polyomavirus transformation and c-fos expression in rat fibroblasts. Oncogene. 7:1992;1837-1845.
26. Yen A., Williams M., Platko J. D., Der C., Hisaka M. Expression of activated RAF accelerates cell differentiation and RB protein down regulation but not hypophosphorylation. Eur. J. Cell Biol. 65:1994;103-113.
27. Yen A., Roberson M. S., Varvayanis S., Lee A. T. Retinoic acid induced MEK dependent MAPK activation needed for eliciting HL-60 cell differentiation and growth arrest. Cancer Res. 58:1998;3163-3172.
28. Cooper G. M. Pathways of mitogenic signal transduction. Oncogenes. 1995;Jones & Bartlett, Boston. p. 279-306.
29. Smolar N., Griffin B. E. DNA sequences of polyoma virus early deletion mutants. J. Virol. 38:1981;958-967.
30. Morgan W. C., Kaplan D. R., Pallas D. C., Roberts T. M. Recombinant retroviruses that transduce middle T antigen cDNAs derived from polyomavirus mutants: Separation of focus formation and soft-agar growth in transformation assays and correlations with kinase activitiesin vitro. J. Virol. 62:1988;3407-3414.
31. c-src. J. Virol. 71:1997;5512-5520.
32. Dilworth S. M., Brewster C. E. P., Jones M. D., Lanfrancone L., Pelicci G., Pelicci P. G. Transformation by polyoma virus middle T antigen involves the binding and tyrosine phosphorylation of Shc. Nature. 367:1994;87-90.
33. Pallas D. C., Fu H., Haehnel L. C., Weller W., Collier R. J., Roberts T. M. Association of polyomavirus middle tumor antigen with 14-3-3 proteins. Science. 265:1994;535-537.
34. Pallas D. C., Shahrik L. K., Martin B. L., Jaspers S., Miller T. B., Brautigan D. L., Roberts T. M. Polyoma small and middle T antigens and SV-40 small T antigen form stable complexes with protein phosphatase 2A. Cell. 60:1990;167-176.
35. Yen A., Reece S. L., Albright K. L. Dependence of HL-60 myeloid cell differentiation on continuous and split retinoic acid exposures: Pre-commitment memory associated with altered nuclear structure. J. Cell Physiol. 118:1984;277-286.
36. Holman P. S., Gjoerup O. V., Davin T., Schaffhausen B. S. Characterization of an immortalizing N-terminal domain of polyomavirus large T antigen. J. Virol. 68:1994;668-673.
37. Gaub M. P., Rochette-Egly C., Lutz Y., Ali S., Matthes H., Schever I., Chambon P. Immunodetection of multiple species of retinoic acid receptor alpha: Evidence for phosphorylation. Exp. Cell Res. 201:1992;335-346.
38. Cherington V., Morgan B., Spiegelman B. M., Roberts T. M. Recombinant retroviruses that transduce individual polyoma tumor antigens: Effects on growth and differentiation. Proc. Natl. Acad. Sci. USA. 83:1986;4307-4311.
39. Yen A., Pardee A. B. Exponential 3T3 cells escape in mid-G1 from their high serum requirement. Exp. Cell Res. 116:1978;103-113.
40. Yen A., Sturgill R., Varvayanis S. Increasing C-FMS expression decreases retinoic acid concentration needed to cause cell differentiation and RB hypophosphorylation. Cancer Res. 57:1997;2020-2028.
41. Saleem A., Yuan Z. M., Taneja N., Rubin E., Kufe D. W., Kharbanda S. M. Activation of serine-threonine protein kinases and early growth response 1 gene expression by tumor necrosis factor in human myeloid leukemia cells. J. Immunol. 154:1995;4150-4156.
42. Waskiewicz A. J., Cooper J. A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell Biol. 7:1995;798-805.
43. Waskiewicz A. J., Flynn A., Proud C. G., Cooper J. A. Mitogen-activated protein kinases activate the serine-threonine kinases Mnk1 and Mnk2. EMBO J. 16:1997;1909-1920.
44. Walter G., Ruediger R., Slaughter C., Mumby M. Association of protein phosphatase 2A with polyoma virus medium tumor antigen. Proc. Natl. Acad. Sci. USA. 87:1990;2521-2525.
45. Sontag E., Federov S., Kamibayashi C., Robbins D., Cobb M., Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell. 75:1993;887-897.
46. Sontag E., Sontag J. M., Garcia A. Protein phosphatase is a critical regulator of protein kinase C ζ signaling targeted by SV40 small T to promote cell growth and NF-κB activation. EMBO J. 16:1997;5662-5671.
47. Mullane K. P., Ratnofsky M., Cullere X., Schaffhausen B. Signaling from polyoma virus middle T and small T defines different roles for protein phosphatase 2a. Mol. Cell. Biol. 18:1998;7556-7564.
48. Frost J., Alberts A., Sontag E., Guan K., Mumby M., Feramisco J. Simian virus small T antigen cooperates with mitogen activated kinases to stimulate AP-1 activity. Mol. Cell. Biol. 14:1994;6244-6252.
49. Kamibayashi C., Estes R., Lickteig R. L., Yang S. I., Craft C., Mumby M. Comparison of heterotrimeric protein phosphatase 2A containing different B subunits. J. Biol. Chem. 269:1994;20139-20148.
50. Wheat W., Roesler W., Klemm D. Simian virus 40 small tumor antigen inhibits dephosphorylation of protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol. Cell. Biol. 14:1994;5881-5890.
51. Kharbanda S., Saleem A., Emoto Y., Stone R., Rapp U., Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J. Biol. Chem. 269:1994;872-878.
52. Townsend K. J., Trusty J. L., Traupman M. A., Eastman A., Craig R. W. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene. 17:1998;1223-1234.
53. Sato E. F., Edashige K., Inoue M., Utsumi K. Okadaic acid increased Annexin I and induced differentiation of human promyelocytic leukemia cells. Biochem. Biophys. Acta. 1266:1995;23-30.
54. Nishikawa M., Omay S. B., Toyoda H., Tawara I., Shima H., Nagao M., Hemmings B. A., Mumby M. C., Deguchi K. Expression of the catalytic and regulatory subunits of protein phosphatase type 2A may be differentially modulated during retinoic acid-induced granulocytic differentiation of HL-60 cells. Cancer Res. 54:1994;4879-4884.
55. Campbell K. S., Ogris E., Burke B., Su W., Auger K. R., Druker B. J., Schaffhausen B. S., Roberts T. M., Pallas D. C. Polyoma middle T antigen interacts with SHC via the NPTY motif in middle T. Proc. Natl. Acad. Sci. USA. 91:1994;6344-6348.
56. Yen A., Brown D., Fishbaugh J. Control of HL-60 monocytic differentiation lineage specificity: A late event occurring after precommitment. Cancer Res. 47:1987;129-134.
57. Yen A., Freeman L., Fishbaugh J. Hydroxyurea induces precommitment during retinoic induced HL-60 terminal myeloid differentiation: Possible involvement of gene amplification. Leuk. Res. 11:1987;63-71.
58. Yen A., Forbes M. E. C-myc down regulation and precommitment in HL-60 cells due to bromodeoxyuridine. Cancer Res. 50:1990;1411-1420.
59. Cepko C. L., Roberts B. E., Mulligan R. C. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell. 37:1984;1053-1062.